Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 11/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | MYLK | Q15746 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30853796 | 1.00 | MAP3K5 (0.43) | MAP3K5ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL30853832 | 0.94 | MAP3K5 (0.45) | MAP3K5ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL22126011 | 0.81 | TNF (0.38) | MAP3K5ALDH1A1TNFMYLK | |
| SCHEMBL6127726 | 0.79 | MAP3K5 (0.48) | MAP3K5TNFMYLK | |
| SCHEMBL857728 | 0.78 | ALDH1A1 (0.43) | ALDH1A1HPGDHSD17B10KDM4EMAOA | |
| SCHEMBL29664258 | 0.76 | MAP4K4 (0.41) | ALDH1A1HPGDHSD17B10KDM4EMAOA | |
| SCHEMBL22738979 | 0.75 | MAP3K5 (0.48) | MAP3K5TNFMYLK | |
| SCHEMBL17180502 | 0.75 | MAP3K5 (0.57) | MAP3K5ALDH1A1HPGDHSD17B10MYLK | |
| SCHEMBL30558025 | 0.73 | MAP3K5 (0.53) | MAP3K5TNFMYLK | |
| SCHEMBL943982 | 0.73 | MAP3K5 (0.53) | MAP3K5TNFMYLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | claimed |
| EP-3363797-A1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2933252-B1 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES INC (US) | 2018-01-03 | — | — | EP | claimed |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | claimed |
| EP-2933252-A1 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-10-21 | — | — | EP | claimed |
| US-9067933-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-06-30 | — | — | US | claimed |
| EP-2454250-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2015-01-14 | — | — | EP | claimed |
| US-8378108-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-02-19 | — | — | US | claimed |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | PHARMAKEA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | PHARMAKEA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3858824-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858824-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-2454250-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008709-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008709-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | MAP3K5 16/4885ALDH1A1 4337/4885HPGD 3015/4885 |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | MAP3K5 16/4885ALDH1A1 4244/4885HPGD 3171/4885 |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | BAX, BAD, BCL2 | MAP3K5 13/4885ALDH1A1 3530/4885HPGD 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.